Navigation Links
Drug Prescribed for Migraines and Seizures Increases Risk of Kidney Stones

Topiramate (Topamax), a drug commonly prescribed to treat seizures and migraine headaches, can increase the propensity of calcium phosphate kidney stones//, researchers at UT Southwestern Medical Center have found.

A study – the largest cross-sectional examination of how the long-term use of topiramate affects kidney-stone formation – appears in the October issue of the American Journal of Kidney Diseases.

Several case reports have described an association between topiramate and the development of kidney stones, but this complication had not been well recognized and physicians have not informed patients about the risk, the UT Southwestern researchers said. More important, the mechanism of stone formation was largely unknown previously.

“The wide-spread and escalating use of topiramate emphasizes the importance of considering the long-term impact of this drug on kidney-stone formation,” said Dr. Khashayar Sakhaee, senior author of the study and chief of mineral metabolism at UT Southwestern.

More than 29 million Americans suffer from migraines, with women being affected three times more often than men, according to the National Headache Foundation.

“Topiramate is probably one of the most commonly prescribed and most effective neurological medications right now,” said Dr. Dion Graybeal, assistant professor of neurology and an author of the study.

Dr. Graybeal and other researchers at UT Southwestern say the next step is to develop a way to block the development of kidney stones for users.

The study comprised two phases. Thirty-two individuals already being treated with topiramate and 50 normal volunteers were enrolled in a cross-sectional study in which their blood and urine were tested for kidney-stone risk. A short-term study also was conducted in seven individuals to assess stone risk before and three months after taking topiramate. All patients were evaluated at UT Southwestern’s G eneral Clinical Research Center.

Researchers found that taking topiramate on a long-term basis, or for about one year, caused systemic metabolic acidosis – a buildup of excessive acid in the blood – as a result of the inability of the kidney to excrete acid. Topiramate use also increased the urine pH and lowered urine citrate, an important inhibitor of kidney-stone formation.

“These changes increase the propensity to form calcium phosphate stones,” Dr. Sakhaee said.

In the short-term study, urinary calcium and oxalate – a chemical compound that binds strongly with calcium and is found in most calcium stones – did not significantly change in people taking topiramate.

Kidney stones are solid deposits that form in the kidneys from substances excreted in the urine. When waste materials in urine do not dissolve completely, microscopic particles begin to form and, over time, grow into kidney stones.

Before this study, the rate of kidney-stone formation with topiramate was reported as 1.5 percent. The low incidence rate may be an underestimation due to the short length of observation and the lack of ongoing kidney-stone surveillance and data collection for this drug, said Dr. Sakhaee, holder of the BeautiControl Cosmetics Inc. Professorship in Mineral Metabolism and Osteoporosis.

“There is a legitimate concern for the occurrence of kidney stones with long-term topiramate treatment,” said Dr. Sakhaee said. “Studies are needed to explore optimal measures to prevent kidney-stone formation with topiramate use.”

Other UT Southwestern researchers contributing to the study were Dr. Orson Moe, director of the Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, Dr. Naim Maalouf, assistant professor of internal medicine and Dr. Brian J. Welch, a postdoctoral fellow in internal medicine.

The research was supported by the National Institutes of Health.

Sourc eNewswise

Related medicine news :

1. Bar Codes For Prescribed Drugs
2. Life-Saving Heart Drug Often Not Prescribed
3. Self-Prescribed Vitamins And Herbal Remedies Can Do More Harm Than Good
4. Statins Prescribed To Those Who Are At a Risk Of Developing A Heart Disease
5. AHRQ Finds Antibiotics Over-Prescribed To Children
6. Exercise to be Prescribed for Robust Health in Elderly
7. Widely Prescribed Diabetes Drug Falls Short of Promise, Says New Review
8. No Dying in Peace for Woman Prescribed Medical Pot
9. Hormones Linked To Migraines
10. Link Between Migraines and Behavioral Disorders
11. Preventive Therapies Found to be More Effective in Managing Migraines
Post Your Comments:

(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: